Nebahat Sunar
Research Subjects
Nebahat Sunar has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Mulaim Sizer
Department of Obstetrics and Gynecology, Batman Training and Research Hospital, Batman, Türkiye
4 shared publications - Hamdin Günsel
Department of Obstetrics and Gynecology, Batman Training and Research Hospital, Batman, Türkiye
3 shared publications - Dicle Akkılıç Dönmez
Clinic of Obstetrics and Gynecology, Dağkapı State Hospital, Diyarbakır, Türkiye
2 shared publications - Gülten Çirkin Tekeş
Sağlık Bilimleri Üniversitesi Etlik Şehir Hastanesi Perinatoloji Kliniği
2 shared publications - Mehmet Sait Icen
Dicle University, School of Medicine
2 shared publications - Adem Yoldas
Department of Obstetrics and Gynecology, Batman Training and Research Hospital, Batman, Türkiye
1 shared publication
Latest Publications
- Open Access
- 30 July 2024
- Published by MediHealth Academy in Journal of Controversies in Obstetrics & Gynecology and Pediatrics
- Vol. 2 (3) , 58-63
The importance of CA-125 and clinical markers in ovarian cancer
Aims: In this study, considering all the known facts about ovarian cancer; The aim of this study is to retrospectively examine the factors related to the etiopathogenesis, diagnosis and prognosis of ovarian cancer, to determine the population at risk, and to try to catch cancer before it progresses or at an early stage by controlling it more frequently and early. Methods: A total of 99 patients who were operated for adnexal mass in Dicle University Faculty of Medicine, Department of Obstetrics and Gynecology between 1 January 2011 and 31 December 2020 and whose final pathology resulted as alignant were included in our study. Patients with borderline results were not included in our study. Of these 99 patients age, gravityparity, menopausal status, presence of additional disease, symptoms, CA-125 level, tumor burden, tumor diameter and structure, presence of ascites, presence of implant, lymph node involvement, frozen pathology result, tumor type, stage, complications were investigated. Results: In this study, the mean age at diagnosis was 51.04 years. It was observed that 55.6% of the patients were postmenopausal. The most common tumor type was identified as epithelial tumors. It has been determined that the patients are mostly in the advanced stage. When the relationship between the stage and the presence of lymph node and ascites fluid was examined, it was observed that lymph node involvement and presence of ascitic fluid increased in advanced stages. It has been observed that the universe progresses as the CA-125 level rises. It has been demonstrated that CA-125 is higher in patients with residual tumors. In addition, CA-125 levels were higher in patients with lymph node involvement than in those without involvement, in patients with bilateral tumours than in those with unilateral tumours, in patients with ascites than in those without ascites, and in epithelial type tumours than in other tumour types. Conclusion: Although scientific research has been carried out on many markers for ovarian cancer, especially Ca-125, it is difficult to detect it at an early stage since routine ovarian cancer screening is not possible under today’s conditions. Even though it is not specific, if some symptoms such as abdominal pain are present in older women, considering ovarian cancer among the preliminary diagnoses may help detect more patients at an early stage.
- 30 July 2024
- Published by MediHealth Academy in Journal of Controversies in Obstetrics & Gynecology and Pediatrics
- Vol. 2 (3) , 58-63
Open AccessThe importance of CA-125 and clinical markers in ovarian cancer
Aims: In this study, considering all the known facts about ovarian cancer; The aim of this study is to retrospectively examine the factors related to the etiopathogenesis, diagnosis and prognosis of ovarian cancer, to determine the population at risk, and to try to catch cancer before it progresses or at an early stage by controlling it more frequently and early. Methods: A total of 99 patients who were operated for adnexal mass in Dicle University Faculty of Medicine, Department of Obstetrics and Gynecology between 1 January 2011 and 31 December 2020 and whose final pathology resulted as alignant were included in our study. Patients with borderline results were not included in our study. Of these 99 patients age, gravityparity, menopausal status, presence of additional disease, symptoms, CA-125 level, tumor burden, tumor diameter and structure, presence of ascites, presence of implant, lymph node involvement, frozen pathology result, tumor type, stage, complications were investigated. Results: In this study, the mean age at diagnosis was 51.04 years. It was observed that 55.6% of the patients were postmenopausal. The most common tumor type was identified as epithelial tumors. It has been determined that the patients are mostly in the advanced stage. When the relationship between the stage and the presence of lymph node and ascites fluid was examined, it was observed that lymph node involvement and presence of ascitic fluid increased in advanced stages. It has been observed that the universe progresses as the CA-125 level rises. It has been demonstrated that CA-125 is higher in patients with residual tumors. In addition, CA-125 levels were higher in patients with lymph node involvement than in those without involvement, in patients with bilateral tumours than in those with unilateral tumours, in patients with ascites than in those without ascites, and in epithelial type tumours than in other tumour types. Conclusion: Although scientific research has been carried out on many markers for ovarian cancer, especially Ca-125, it is difficult to detect it at an early stage since routine ovarian cancer screening is not possible under today’s conditions. Even though it is not specific, if some symptoms such as abdominal pain are present in older women, considering ovarian cancer among the preliminary diagnoses may help detect more patients at an early stage.
- 1 July 2024
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 15 (7) , 495-499
Comparison of serum neuropeptide-ff and catestatin levels in hypertensive pregnant women
Aim We aimed to compare the levels of Neuropeptide-FF and Catestatin in the sera of hypertensive and normotensive pregnant women, to determine the possible changes in hypertensive diseases of pregnancy and to examine the possible place of pregnancy in hypertensive diseases. Methods We used the quantitative analysis method to test the hypotheses of the research and examine the relationship between variables. Neuropeptide FF and Catestatin levels were analyzed by Enzyme Linked Immunoassay (ELISA) method. Neuropeptide-FF and Catestatin values of patient and control groups were analyzed with Mann-Whitney and Chi-square tests. Results A higher Catestatin value was determined in the patient group compared to the control group, and this difference was statistically significant(P < .001). Catestatin value in the patient group was 31.61 ± 12.54, and value in the control group was 48.46 ± 22.45 and the relation was statistically found significant (P < .05). The neuropeptide-FF was not statistically significant in the patient and control group compared to the control group (P = .916). Therefore, the Neuropeptide-FF value in the patient group was 134.30 ± 93.72; this value was found as 139.49 ± 96.41 in the control group, but the relation statistically was not found significant (P > .05). According to the analysis results of our study, a statistically significant difference was found for Catestatin at the 5% significance level between the patient group and the control group. Conclusion Decreased NPFF expression in the hypothalamus of hypertensive patients may lead to impaired interaction with other neurochemical systems and therefore may play a role in the pathogenesis of hypertensive disease.
- 1 July 2024
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 15 (7) , 495-499
Comparison of serum neuropeptide-ff and catestatin levels in hypertensive pregnant women
Aim We aimed to compare the levels of Neuropeptide-FF and Catestatin in the sera of hypertensive and normotensive pregnant women, to determine the possible changes in hypertensive diseases of pregnancy and to examine the possible place of pregnancy in hypertensive diseases. Methods We used the quantitative analysis method to test the hypotheses of the research and examine the relationship between variables. Neuropeptide FF and Catestatin levels were analyzed by Enzyme Linked Immunoassay (ELISA) method. Neuropeptide-FF and Catestatin values of patient and control groups were analyzed with Mann-Whitney and Chi-square tests. Results A higher Catestatin value was determined in the patient group compared to the control group, and this difference was statistically significant(P < .001). Catestatin value in the patient group was 31.61 ± 12.54, and value in the control group was 48.46 ± 22.45 and the relation was statistically found significant (P < .05). The neuropeptide-FF was not statistically significant in the patient and control group compared to the control group (P = .916). Therefore, the Neuropeptide-FF value in the patient group was 134.30 ± 93.72; this value was found as 139.49 ± 96.41 in the control group, but the relation statistically was not found significant (P > .05). According to the analysis results of our study, a statistically significant difference was found for Catestatin at the 5% significance level between the patient group and the control group. Conclusion Decreased NPFF expression in the hypothalamus of hypertensive patients may lead to impaired interaction with other neurochemical systems and therefore may play a role in the pathogenesis of hypertensive disease.
- 1 June 2024
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 15 (6) , 439-443
Evaluation of maternal and fetal outcomes in pregnant women with gestational thrombocytopenia
Aim Investigate the relationship between gestational thrombocytopenia (GT) and adverse maternal and fetal outcomes in pregnant women. Methods 97 patients who were diagnosed with gestational thrombocytopenia during pregnancy, had no other disease that causes thrombocytopenia and delivered in our clinic were included in the study. The patients were divided into two groups according to their platelet values. Group-1 platelet count was <70.000/mm3 and Group-2 platelet count was 70.000- 150.000/mm3. In the analysis of negative perinatal outcomes, logistic regression analysis was performed. P < .05 was considered significant in the analysis results. Results From the laboratory data of the patients diagnosed with gestational thrombocytopenia, the mean platelet count was 85.28 ± 27.08 (min-max: 22-142) and mean hematocrit was 35.91 ± 3.63 (min-max: 21-45). When the groups were evaluated considering their hematocrit values; the mean hematocrit value of the patients in Group-2 (36.42 ± 3.22) was higher than the mean hematocrit value (34.26 ± 4.39) of the patients in Group-1, and a significant difference was found between them (p:0.03). This significant difference was also present when the platelet value was taken as the limit of 110,000 (p:0.039). Conclusion Apgar scores are lower in patients diagnosed with gestational thrombocytopenia and with platelet values below 70,000, and the need for blood transfusion (erythrocyte suspension, FFP (Fresh Frozen Plasma) and platelet product) is higher. The need for erythrocyte transfusion continues even when the platelet limit is 80,000, and the need for platelet transfusion is 100,000.
- 1 June 2024
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 15 (6) , 439-443
Evaluation of maternal and fetal outcomes in pregnant women with gestational thrombocytopenia
Aim Investigate the relationship between gestational thrombocytopenia (GT) and adverse maternal and fetal outcomes in pregnant women. Methods 97 patients who were diagnosed with gestational thrombocytopenia during pregnancy, had no other disease that causes thrombocytopenia and delivered in our clinic were included in the study. The patients were divided into two groups according to their platelet values. Group-1 platelet count was <70.000/mm3 and Group-2 platelet count was 70.000- 150.000/mm3. In the analysis of negative perinatal outcomes, logistic regression analysis was performed. P < .05 was considered significant in the analysis results. Results From the laboratory data of the patients diagnosed with gestational thrombocytopenia, the mean platelet count was 85.28 ± 27.08 (min-max: 22-142) and mean hematocrit was 35.91 ± 3.63 (min-max: 21-45). When the groups were evaluated considering their hematocrit values; the mean hematocrit value of the patients in Group-2 (36.42 ± 3.22) was higher than the mean hematocrit value (34.26 ± 4.39) of the patients in Group-1, and a significant difference was found between them (p:0.03). This significant difference was also present when the platelet value was taken as the limit of 110,000 (p:0.039). Conclusion Apgar scores are lower in patients diagnosed with gestational thrombocytopenia and with platelet values below 70,000, and the need for blood transfusion (erythrocyte suspension, FFP (Fresh Frozen Plasma) and platelet product) is higher. The need for erythrocyte transfusion continues even when the platelet limit is 80,000, and the need for platelet transfusion is 100,000.
- 1 May 2024
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 15 (5) , 369-372
The role of hemogram parameters in predicting the severity of preeclampsia
Aim The purpose of this study was to examine the significance of hemogram parameters in predicting preeclampsia and/or preeclampsia severity in patients with pre-diagnosis of preeclampsia. Methods The study was retrospective and comprised 198 patients with preeclampsia, 158 with severe preeclampsia and 40 with non-severe preeclampsia, as well as 126 pregnant women who had a healthy pregnancy as the control group. From the hemogram parameters, platelet count (PLT), neutrophil count, mean platelet volume (MPV), mean erythrocyte volume (MCV), leukocyte count and neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (TLR) and platelet/neutrophil ratio (TNR) were calculated. The pregnant women included in the study were compared in terms of these parameters. Results While there was no statistically significant difference between the groups in the statistical analysis of MCV, MPV, NLR, and TNO, which are the parameters studied in PE groups with and without severe features, a statistically significant difference was found in these parameters between the control group and the preeclampsia group. At the TNO 35,1250 cut-off value, the sensitivity was 83.8 %, the specificity was 41.3 %, the positive predictive value was 69.17 %, and the negative predictive value was 61.90 %, and it was found that this value predicted the presence of PE as 69%. Conclusion In this study, we discovered that MPV, MCV, TNO, and NLO levels differed significantly between the PE and control groups. However, the sensitivity and specificity rates of these parametria in the detection of preeclampsia are far below significant values.
- 1 May 2024
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 15 (5) , 369-372
The role of hemogram parameters in predicting the severity of preeclampsia
Aim The purpose of this study was to examine the significance of hemogram parameters in predicting preeclampsia and/or preeclampsia severity in patients with pre-diagnosis of preeclampsia. Methods The study was retrospective and comprised 198 patients with preeclampsia, 158 with severe preeclampsia and 40 with non-severe preeclampsia, as well as 126 pregnant women who had a healthy pregnancy as the control group. From the hemogram parameters, platelet count (PLT), neutrophil count, mean platelet volume (MPV), mean erythrocyte volume (MCV), leukocyte count and neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (TLR) and platelet/neutrophil ratio (TNR) were calculated. The pregnant women included in the study were compared in terms of these parameters. Results While there was no statistically significant difference between the groups in the statistical analysis of MCV, MPV, NLR, and TNO, which are the parameters studied in PE groups with and without severe features, a statistically significant difference was found in these parameters between the control group and the preeclampsia group. At the TNO 35,1250 cut-off value, the sensitivity was 83.8 %, the specificity was 41.3 %, the positive predictive value was 69.17 %, and the negative predictive value was 61.90 %, and it was found that this value predicted the presence of PE as 69%. Conclusion In this study, we discovered that MPV, MCV, TNO, and NLO levels differed significantly between the PE and control groups. However, the sensitivity and specificity rates of these parametria in the detection of preeclampsia are far below significant values.